Latest From Abivax
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
The French biotech's CEO tells Scrip the firm now has the time and resources to sign up a big pharma partner for its ulcerative colitis, RA and Crohn’s candidate.
Abivax Phase IIa data for its lead asset showed impressive results in ulcerative colitis. The biotech's CEO tells Scrip trials in Crohn's disease and rheumatoid arthritis will now follow.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Senior Management
Hartmut J Ehrlich, PhD, CEO
Didier Blondel, CFO
Pierre Courteille, Chief Commercial Officer & VP, Bus. Dev.
Jean-Marc Steens, MD, CMO
Didier Scherrer, PhD, VP, R&D
- Contact Info
Phone: 1 53 83 08 41
5, rue de la Baume
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.